Hayashi M
Pathophysiology. 2023; 30(4):599-617.
PMID: 38133144
PMC: 10747330.
DOI: 10.3390/pathophysiology30040043.
Sinmaz N, Nguyen T, Tea F, Dale R, Brilot F
J Neuroinflammation. 2016; 13(1):219.
PMID: 27577085
PMC: 5006540.
DOI: 10.1186/s12974-016-0678-4.
Onugoren M, Golombeck K, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M
Neurol Neuroimmunol Neuroinflamm. 2016; 3(2):e207.
PMID: 26977423
PMC: 4772911.
DOI: 10.1212/NXI.0000000000000207.
Mappouras D, Philippou G, Haralambous S, Tzartos S, Balafas A, Souvatzoglou A
Clin Exp Immunol. 1995; 100(2):336-43.
PMID: 7743674
PMC: 1534338.
DOI: 10.1111/j.1365-2249.1995.tb03674.x.
Graus Y, De Baets M
Immunol Res. 1993; 12(1):78-100.
PMID: 7685805
DOI: 10.1007/BF02918370.
Anti-acetylcholine receptor antibodies.
Vincent A, Newsom Davis J
J Neurol Neurosurg Psychiatry. 1980; 43(7):590-600.
PMID: 7400823
PMC: 490626.
DOI: 10.1136/jnnp.43.7.590.
Circulating immune complexes in myasthenia gravis: a study in relation to thymectomy, clinical severity and thymus histology.
Bartoloni C, Guidi L, Scoppetta C, Tonali P, Bartoccioni E, Flamini G
J Neurol Neurosurg Psychiatry. 1981; 44(10):901-5.
PMID: 7310408
PMC: 491175.
DOI: 10.1136/jnnp.44.10.901.
Receptor dysfunctions in human disease.
BLOCK L, Tenschert W, Locher R, Siegenthaler W, Vetter W
Klin Wochenschr. 1981; 59(8):355-63.
PMID: 6270449
DOI: 10.1007/BF01698513.
Mechanisms of acetylcholine receptor loss in myasthenia gravis.
Drachman D, Adams R, Stanley E, Pestronk A
J Neurol Neurosurg Psychiatry. 1980; 43(7):601-10.
PMID: 6249894
PMC: 490627.
DOI: 10.1136/jnnp.43.7.601.
Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor.
Brenner T, Beyth Y, Abramsky O
Proc Natl Acad Sci U S A. 1980; 77(6):3635-9.
PMID: 6158053
PMC: 349672.
DOI: 10.1073/pnas.77.6.3635.
Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
Bach J, Morel E
Clin Exp Immunol. 1987; 68(1):130-7.
PMID: 3652512
PMC: 1542690.
Immunopathologic events at the endplate in myasthenia gravis.
Ashizawa T, Appel S
Springer Semin Immunopathol. 1985; 8(3):177-96.
PMID: 2413561
DOI: 10.1007/BF00197295.
Direct method for detection and characterization of cell surface receptors for insulin by means of 125I-labeled autoantibodies against the insulin receptor.
Jarrett D, Roth J, Kahn C, Flier J
Proc Natl Acad Sci U S A. 1976; 73(11):4115-9.
PMID: 1069300
PMC: 431349.
DOI: 10.1073/pnas.73.11.4115.
Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man.
Flier J, Kahn C, Jarrett D, Roth J
J Clin Invest. 1976; 58(6):1442-9.
PMID: 993353
PMC: 333316.
DOI: 10.1172/JCI108600.
Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.
Zurn A, Fulpius B
Clin Exp Immunol. 1976; 24(1):9-17.
PMID: 949876
PMC: 1538497.
Long-term effect of glucocorticosteroids on neuromuscular blocking in mice.
Arts W, OOSTERHUIS H
J Neurol Neurosurg Psychiatry. 1977; 40(7):675-7.
PMID: 915511
PMC: 492798.
DOI: 10.1136/jnnp.40.7.675.
Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action.
Kahn C, Baird K, Filier J, Jarrett D
J Clin Invest. 1977; 60(5):1094-106.
PMID: 908753
PMC: 372462.
DOI: 10.1172/JCI108861.
A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.
Monnier V, Fulpius B
Clin Exp Immunol. 1977; 29(1):16-22.
PMID: 891031
PMC: 1541026.
A case of myasthenia gravis treated with steroids: some suggestions for the mechanisms underlying their effect.
Dandona P, Corkan E, Sladen G
Postgrad Med J. 1977; 53(620):321-4.
PMID: 887530
PMC: 2496642.
DOI: 10.1136/pgmj.53.620.321.
A membrane-associated autoantibody in a case of myasthenia gravis with chronic hepatitis.
Fairfax A, Doniach D, Wells C
Clin Exp Immunol. 1976; 25(3):383-8.
PMID: 786517
PMC: 1541407.
